Mirna Therapeutics Inc Receives a Hold from H.C. Wainwright

By Jason Carr

In a report released today, Shaunak Deepak from H.C. Wainwright reiterated a Hold rating on Mirna Therapeutics Inc (NASDAQ: MIRN). The company’s shares opened today at $1.21, close to its 52-week low of $1.12.

According to TipRanks.com, Deepak is ranked 0 out of 5 stars with an average return of -12.7% and a 45.2% success rate. Deepak covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Karyopharm Therapeutics, and Fate Therapeutics.

Mirna Therapeutics Inc has an analyst consensus of Hold, with a price target consensus of $1.75.

Based on Mirna Therapeutics Inc’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $0 and GAAP net loss of $5.37 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $6.23 million.

Mirna Therapeutics, Inc. is a discovery-stage biotechnology that engages in the research and development of microRNA-directed oncology therapies. It its lead product is the MRX34, a product designed to deliver a mimic of the naturally occurring microRNA tumor suppressor miR-34, which is under expressed in a wide variety of cancers. The company was founded in 2007 and is headquartered in Austin, TX